ViRob

ViRob is an innovative biotechnology company focused on developing a novel class of anti-bacterial therapies to combat the global threat of antibiotic resistance. The company utilizes a proprietary platform that engineers bacteriophages to serve as highly specific delivery vehicles for therapeutic payloads, effectively neutralizing multi-drug resistant bacteria. By combining the natural targeting capabilities of phages with advanced synthetic biology, ViRob aims to provide precise treatments for chronic and acute infections, including those associated with cystic fibrosis and hospital-acquired pneumonia. Their approach is designed to minimize damage to the healthy microbiome while providing a potent alternative to traditional antibiotics.